Speakers

Prof. Dr. Malcolm BrennerBaylor College of Medicine (BCM), Houston/USA

Prof. Dr. Eric Gottwald, Karlsruher Institut für Technologie(KIT)

Prof. Dr. Peter Lang, Universitätsklinikum Tübingen

PD Dr. Uta Höpken, MDC Max-Delbrück-Centrum, Berlin

Prof. Dr. Michael Hudecek, Uniklinikum Würzburg

Dr. Armin Rehm, MDC Max-Delbrück-Centrum, Berlin

Prof. Dr. Dr. h.c. Christof Scheid, Uniklinik Köln

Prof. Dr. Marion Subklewe, LMU München

PD Dr. Simone Thomas, Universitätsklinikum Regensburg

PD Dr. Patrick Wuchter, Transfusionsmedizin,Universitätsmedizin Mannheim

Prof. Dr. Andreas Kulozik, Pädiatrische Onkologie, Zentrumfür Kinder- und Jugendmedizin, UniversitätsklinikumHeidelberg

Dr. Patrick DerigsPD Dr. Sascha DietrichProf. Dr. Peter DregerProf. Dr. Hartmut GoldschmidtProf. Dr. Carsten Müller-TidowDr. Tim SauerDr. Maria-Luisa SchubertPD Dr. Anita SchmittProf. Dr. Michael SchmittDr. Lei WangMedizinische Klinik V (Hämatologie, Onkologie undRheumatologie), Universitätsklinikum Heidelberg

Sponsors Venue

Heidelberg Marriott Hotel

Vangerowstraße 1669115 Heidelberg

Train StationHeidelberg Main Train Station 0.8 km away from hotel

Bus StationBetriebshof 0.5 km away from hotel 3rd CELL THERAPY SYMPOSIUM

October 25 & 26, 2019

Heidelberg Marriott Hotel Vangerowstraße 16 69115 Heidelberg

Department of Medicine V (Hematology, Oncology and Rheumatology)

PLATINUM: 20.000,-

15.000,-

Gold: 5.000,-

Silver: 3.500,-

3.000,-

2.500,-

2.000,-

Bronze: 1.500,-

1.500,-

1.500,-

1.000,-

850,-

Dear colleagues,

Since our last Cell Therapy Symposium only one year haselapsed. Within this short period of time, tremendousprogress has been made in our clinic regarding CAR T cellstherapy: more than thirty patients have received thisinnovative treatment. On the global level more than 2000patients have been treated for acute leukemia, Non-Hodgkin lymphoma and myeloma with remarkable success.Therefore the therapeutical algorithms for the treatment ofthese diseases need to be revisited. Moreover, the safemanagement of cytokine release syndrome, neurotoxicityand prolonged cytopenia will be highlighted in thissymposium. In addition, novel targets and preclinicalresearch for further development of immunogene therapywill be discussed.We are very proud to present a panel of speakers from themajor CAR T cell centers in Germany to give an update of thecurrent status. Also, we are very excited that we could winProf. Brenner from the Baylor’s College of Medicine,Houston/USA to give a key note lecture on his impressiveachievements in the field of immuno cell therapy.

We are looking forward to welcoming you to our symposium.

With very warm regards from Heidelberg

Michael Schmitt Carsten Müller-Tidow

Peter Dreger

The participation is free of charge.

The meeting has been certified from theLandesärztekammerand 9 CME points are granted.

To ensure proper organization, we welcome you toregister by short mail toRegina.Hollenbach@med.uni-heidelberg.delatest October 1st, 2019.

Program – Day 1

12:00 Registration

13:00 Welcome addressCarsten Müller-Tidow / Michael Schmitt

Chairs:Carsten Müller-Tidow / Michael Schmitt

13:10 Status of the Heidelberg HD-CAR-1StudyMichael Schmitt

13:30 CART Real World: Experience withcommercial CARTs in HDPeter Dreger

13:50 CD70 and CD96 as novel targets forCAR T cell therapy in myeloid diseaseTim Sauer

14:10 Status of clinical CAR-T cell therapyand translation of the transposontechnique in IITs in WürzburgMichael Hudecek

14:30 Gene therapy for thalassemia patientsAndreas Kulozik

14:50 Automated cell processingArmin Rehm

15:10 Coffee break

Chairs:Tim Sauer / Sascha Dietrich

15:40 Practical side effect management inCAR-T cell therapyMaria-Luisa Schubert

16:00 Leukapheresis for CARs - status and regulatory affairsAnita Schmitt

16:20 BCMA CAR-T cells in myelomapatientsHartmut Goldschmidt

16:40 CAR-T cell production and therapy inTübingenPeter Lang

17:00 CAR-T cell therapy in KölnChristof Scheid

17:20 KEY NOTE: Houston News on CAR Tcell therapy and beyondMalcolm Brenner

18:15 End of Day 1

Program - Day 2

Chairs: Eric Gottwald / Maria-Luisa Schubert

09:00 CMV reactivation aftertransplantation of stem cells or CARsPatrick Derigs

09:20 Biomarkers for patients undergoingExtracorporeal PhotopheresisLei Wang

09:40 Status of clinical CAR-T cell therapy inMunichMarion Subklewe

10:00 Cord blood-banking: to what end?Patrick Wuchter

10:20 Novel CAR constructs for multiplemyelomaUta Höpken

10:40 Coffee break

Chairs:Anita Schmitt / Peter Dreger

11:10 CAR T cell culture in bioreactorsEric Gottwald

11:30 Which drugs should we add to CAR Tcell therapy?Sascha Dietrich

11:50 PRAME-TCR therapy of patients withAML/MDS or myelomaSimone Thomas

12:10 Closing Remarks/AdjournMichael Schmitt

12:30 End of Symposium